Jazz Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Jazz Pharmaceuticals plc
Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.
The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies.
The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.
EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.
- Contract Manufacturing Organization
- Drug Discovery Tools
- Other Names / Subsidiaries
- Alizé Pharma II
- Azur Pharma Public Limited Company
- Cavion, Inc.
- Cavion LLC (Tau Therapeutics LLC
- Xdynia LLC)
- Celator Pharmaceuticals, Inc.
- EUSA Pharma Inc. (Cytogen Corporation
- OPi SA)
- Gentium S.p.A.
- GW Pharmaceuticals plc
- Jazz Pharmaceuticals Ireland Limited
- Orphan Medical, Inc.